The DPP4 Inhibitors Market stands as a cornerstone in contemporary diabetes therapeutics, representing a paradigm shift in type 2 diabetes management protocols. These sophisticated oral agents operate by selectively inhibiting the dipeptidyl peptidase-4 enzyme, effectively prolonging incretin hormone activity that modulates glycemic control. As the global diabetes burden intensifies,...